Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 19/20 | 0.69 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130126 | 0.92 | CLPP (0.71) | CLPPPDE1BKCNH2CYP3A4 | |
| SCHEMBL24914493 | 0.90 | CLPP (0.60) | CLPPPDE1BKCNH2CYP3A4 | |
| SCHEMBL24914492 | 0.90 | CLPP (0.72) | CLPPPDE1BKCNH2CYP3A4 | |
| SCHEMBL24914748 | 0.88 | CLPP (0.71) | CLPPCYP3A4 | |
| SCHEMBL30130152 | 0.87 | CLPP (0.73) | CLPPPDE1BKCNH2CYP3A4 | |
| SCHEMBL24915165 | 0.84 | CLPP (0.73) | CLPPCYP3A4 | |
| SCHEMBL24914845 | 0.82 | CLPP (0.64) | CLPPPDE1BKCNH2CYP3A4 | |
| SCHEMBL24915164 | 0.82 | CLPP (1.00) | CLPPCYP3A4 | |
| SCHEMBL22028759 | 0.78 | CLPP (0.75) | CLPP | |
| SCHEMBL24914481 | 0.77 | CLPP (0.60) | CLPPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | claimed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | claimed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | claimed |
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | CLPP 7/4885PDE1B 1214/4885KCNH2 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.